The estimated Net Worth of Christopher S. Boerner is at least $14.2 Million dollars as of 10 March 2024. Mr. Boerner owns over 54,638 units of Bristol-Myers Squibb Co stock worth over $6,305,476 and over the last 13 years he sold BMY stock worth over $2,187,041. In addition, he makes $5,741,650 as Executive Vice President and Chief Commercial Officer at Bristol-Myers Squibb Co.
Christopher has made over 18 trades of the Bristol-Myers Squibb Co stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 54,638 units of BMY stock worth $2,654,860 on 10 March 2024.
The largest trade he's ever made was exercising 59,111 units of Bristol-Myers Squibb Co stock on 10 March 2023 worth over $2,872,203. On average, Christopher trades about 12,559 units every 174 days since 2011. As of 10 March 2024 he still owns at least 129,769 units of Bristol-Myers Squibb Co stock.
You can see the complete history of Mr. Boerner stock trades at the bottom of the page.
Dr. Christopher S. Boerner, Ph.D., is Executive Vice President and Chief Commercial Officer of the Company. He most recently served as the Company’s head of international markets from October 2017 to August 2018. He joined the Company in February 2015 as head of the U.S. commercial organization and served in that role until October 2017. Prior to joining the Company, he was with Seattle Genetics, Inc., where he served as executive vice president of commercial from 2014 to 2015 and senior vice president of commercial from 2012 to 2014. Before joining Seattle Genetics, Mr. Boerner was with Dendreon Corporation, where he led the marketing team. From 2002 to 2010, he worked at Genentech, a member of the Roche Group, where he served in a variety of commercial roles, including director of marketing on Avastin, director of Avastin franchise strategy and associate director of oncology market development.
As the Executive Vice President and Chief Commercial Officer of Bristol-Myers Squibb Co, the total compensation of Christopher Boerner at Bristol-Myers Squibb Co is $5,741,650. There are 3 executives at Bristol-Myers Squibb Co getting paid more, with Giovanni Caforio having the highest compensation of $18,767,300.
Christopher Boerner is 49, he's been the Executive Vice President and Chief Commercial Officer of Bristol-Myers Squibb Co since 2018. There are 34 older and 1 younger executives at Bristol-Myers Squibb Co. The oldest executive at Bristol-Myers Squibb Co. is Vicki Sato, 71, who is the Lead Independent Director.
Christopher's mailing address filed with the SEC is BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NJ, 08543.
Over the last 17 years, insiders at Bristol-Myers Squibb Co have traded over $318,151,721 worth of Bristol-Myers Squibb Co stock and bought 211,503 units worth $6,601,565 . The most active insiders traders include Lamberto Andreotti, James M Cornelius, and Giovanni Caforio. On average, Bristol-Myers Squibb Co executives and independent directors trade stock every 8 days with the average trade being worth of $1,682,720. The most recent stock trade was executed by Cari Gallman on 1 August 2024, trading 1,061 units of BMY stock currently worth $51,554.
The Bristol-Myers Squibb Company is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the worlds largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.
Bristol-Myers Squibb Co executives and other stock owners filed with the SEC include: